Compare UK prices. 40+ products · 17 retailers scored
PeptideClear UK

FAQ · Research peptides

Are research peptides on the WADA prohibited list?

Yes. Most research peptides commonly sold in the UK appear on the World Anti-Doping Agency (WADA) prohibited list under section S2 (peptide hormones, growth factors and related substances). BPC-157, TB-500, MOTS-c, Ipamorelin, GHRP-2/6, CJC-1295, Tesamorelin, Sermorelin, and IGF-1 are all prohibited at all times (in and out of competition). SARMs (commonly sold alongside research peptides) are prohibited under section S1.2. Tested athletes under UKAD, World Athletics, or international federation jurisdiction must avoid these substances regardless of "research use only" framing.

Section S2 prohibited peptides

Section S1.2: SARMs

Selective Androgen Receptor Modulators (Ostarine, LGD-4033, RAD-140, Andarine) are not peptides but are commonly sold alongside them by UK retailers like Direct Sarms. They sit under section S1.2 (other anabolic agents) on the WADA list. Equally prohibited at all times.

"In and out of competition"

Section S2 substances are prohibited at all times, not just on competition days. There is no off-season "wash-out window" that makes these substances safe for a tested athlete. Detection methods for metabolites of many peptides extend well beyond use periods, and any positive test results in a violation.

Therapeutic Use Exemptions (TUEs)

Some prohibited substances can be used with a TUE when there is a documented medical need and a licensed prescription. The S2 peptides above almost never qualify because they have no UK MHRA marketing authorisation as medicines; there is therefore no licensed therapeutic use for which an exemption could apply. Tesamorelin is the partial exception (FDA-approved in the US for HIV-associated lipodystrophy under EGRIFTA brand) but UK TUE administration is complex without a UK licence.

What athletes should do

Related: WADA list deep-dive · UK retailers.

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-20